LBRX — LB Pharmaceuticals Inc Stock Price, Chart & AI Report

Positive Oct 9, 2026 • 20:42 UTC GlobeNewswire Inc. • Na

LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals Inc announced equity awards to newly appointed Chief Medical Officer Dr. Susan G. Kozauer and Chief Financial Officer Joseph Miller. Each executive received options to purchase 200,000 shares at an exercise price of $37.22, vesting over 4 years with a 10-year term. The grants were made as inducement awards under Nasdaq Listing Rule 5635(c)(4).

LBRX equity awards Chief Medical Officer Chief Financial Officer stock options inducement grant neuromedicines LB-102

Sentiment note

The company is making strategic executive appointments with competitive equity compensation packages, indicating confidence in leadership and growth trajectory. The appointment of experienced executives to key positions (CMO and CFO) suggests organizational strengthening and preparation for advancing their lead product candidate LB-102 through development stages.

Positive Jul 22, 2026 • 12:00 UTC GlobeNewswire Inc. • Lb Pharmaceuticals Inc

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

LB Pharmaceuticals announced that its Phase 3 NOVA-2 trial of LB-102 for schizophrenia will report topline results in the first half of 2027, ahead of previous guidance. The accelerated timeline reflects faster-than-expected enrollment across 25 U.S. sites. The company maintains sufficient cash runway through Q2 2029 to fund multiple clinical readouts, including Phase 2 trials in bipolar depression and adjunctive MDD.

LBRX LB-102 Phase 3 NOVA-2 trial schizophrenia antipsychotic clinical trial acceleration FDA pre-NDA meeting bipolar depression

Sentiment note

The company accelerated its clinical trial timeline due to faster-than-expected enrollment, demonstrating strong execution and market interest in LB-102. The drug showed positive Phase 2 data with rapid onset, favorable safety profile, and broad therapeutic potential. Strong cash position through Q2 2029 supports multiple ongoing trials.

Positive Jul 10, 2026 • 20:38 UTC GlobeNewswire Inc. • Na

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals Inc (Nasdaq: LBRX) announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. As an inducement to join the company, Zergebel received an equity award of options to purchase 75,000 shares at an exercise price of $32.95 per share, vesting over 4 years. The company continues advancing its lead candidate LB-102, a novel antipsychotic in Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression.

LBRX equity award stock options clinical operations LB-102 antipsychotic Phase 3 trial schizophrenia

Sentiment note

The company is making strategic executive hires for key leadership positions in clinical operations, indicating progress in advancing its pipeline. The appointment of a Senior VP of Clinical Operations suggests the company is scaling operations to support late-stage development of LB-102, with positive Phase 2 data already reported and pivotal Phase 3 trials underway. This demonstrates confidence in the program's advancement.

Positive Feb 27, 2026 • 16:44 UTC Benzinga • Prnewswire

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.

ATAI DFTX GHRS LBRX psychedelic biotechnology Phase 3 trials treatment-resistant depression generalized anxiety disorder

Sentiment note

Initiated Phase 2 ILLUMINATE-1 trial for bipolar depression with 320 patients, Phase 2 schizophrenia data showed statistically significant benefits, secured $100M private placement funding, and positioned as potential first benzamide antipsychotic approved in the U.S.

Positive Feb 5, 2026 • 13:00 UTC GlobeNewswire Inc. • Na

LB Pharmaceuticals Announces $100.0 Million Private Placement

LB Pharmaceuticals Inc (LBRX) announced a $100 million private placement of common stock and pre-funded warrants at $21.17 per share from institutional investors. The company plans to use proceeds to fund a Phase 2 trial for LB-102 as an adjunctive treatment for major depressive disorder, with closing expected on February 6, 2026.

LBRX private placement capital raise LB-102 Phase 2 trial major depressive disorder institutional investors biopharmaceutical

Sentiment note

The company successfully secured $100 million in funding from reputable institutional investors, demonstrating investor confidence. The capital will advance their lead product candidate LB-102 into Phase 2 trials for additional indications, representing meaningful progress in their clinical development pipeline.

Positive Jan 6, 2026 • 12:00 UTC GlobeNewswire Inc. • Lb Pharmaceuticals, Inc

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

LB Pharmaceuticals announced the appointments of Ellen Rose as Senior Vice President of Corporate Affairs and Lindsay Beaupre as Senior Vice President of People and Culture. Both executives bring extensive experience from leading biopharmaceutical and financial services companies. The appointments come as the company advances LB-102, its novel benzamide candidate, into Phase 3 trials for schizophrenia and Phase 2 trials for bipolar depression.

LBRX leadership appointments corporate affairs people and culture LB-102 schizophrenia bipolar depression clinical development

Sentiment note

The company is strengthening its executive leadership team with experienced hires from reputable organizations (Lyell Immunopharma, Prothena, Johnson & Johnson, Vertex Pharmaceuticals, Immunogen). This demonstrates organizational growth and confidence in advancing LB-102 through critical clinical development phases. The appointments support the company's strategic expansion during a transformative period.